TD Asset Management Inc Has $8.21 Million Holdings in Dyne Therapeutics, Inc. $DYN

TD Asset Management Inc increased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1,959.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 419,756 shares of the company’s stock after buying an additional 399,374 shares during the quarter. TD Asset Management Inc owned 0.29% of Dyne Therapeutics worth $8,210,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in DYN. AQR Capital Management LLC acquired a new stake in Dyne Therapeutics during the 1st quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after buying an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its stake in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after buying an additional 366,183 shares during the period. Caxton Associates LLP acquired a new stake in Dyne Therapeutics during the 1st quarter worth $157,000. Finally, Creative Planning raised its stake in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after buying an additional 2,797 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of the stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the completion of the transaction, the director directly owned 11,663 shares in the company, valued at $229,527.84. This represents a 96.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have bought 9,000 shares of company stock worth $156,800 and have sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $17.92 on Wednesday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -5.57 and a beta of 1.09. The stock’s 50-day moving average is $18.26 and its 200-day moving average is $18.22. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the business earned ($1.05) earnings per share. Equities analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on DYN shares. Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright cut their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.